These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2037145)

  • 1. The molecular basis of halothane-induced hepatitis.
    Kenna JG
    Biochem Soc Trans; 1991 Feb; 19(1):191-5. PubMed ID: 2037145
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular basis of halothane hepatitis.
    Gut J
    Arch Toxicol Suppl; 1998; 20():3-17. PubMed ID: 9442277
    [No Abstract]   [Full Text] [Related]  

  • 3. Halothane hepatitis: a model of immune mediated drug hepatotoxicity.
    Neuberger J; Kenna JG
    Clin Sci (Lond); 1987 Mar; 72(3):263-70. PubMed ID: 3545644
    [No Abstract]   [Full Text] [Related]  

  • 4. Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase.
    Martin JL; Kenna JG; Martin BM; Thomassen D; Reed GF; Pohl LR
    Hepatology; 1993 Oct; 18(4):858-63. PubMed ID: 8406360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific antibodies to halothane-induced liver antigens in halothane-associated hepatitis.
    Kenna JG; Neuberger J; Williams R
    Br J Anaesth; 1987 Oct; 59(10):1286-90. PubMed ID: 3676056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies to hepatic microsomal carboxylesterase in halothane hepatitis.
    Smith GC; Kenna JG; Harrison DJ; Tew D; Wolf CR
    Lancet; 1993 Oct; 342(8877):963-4. PubMed ID: 8105217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of repeated 14C halothane exposure in mice.
    Stoyka WW; Havasi G
    Can Anaesth Soc J; 1977 Mar; 24(2):243-51. PubMed ID: 843976
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunological aspects of halothane hepatitis. Possible relevance of biotransformation.
    Walton B
    Acta Anaesthesiol Belg; 1975; 23 Suppl():155-9. PubMed ID: 1231479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane.
    Hubbard AK; Roth TP; Gandolfi AJ; Brown BR; Webster NR; Nunn JF
    Anesthesiology; 1988 May; 68(5):791-6. PubMed ID: 3369720
    [No Abstract]   [Full Text] [Related]  

  • 10. Halothane hepatitis and the anaesthesiologist.
    Shipton EA; Kruger AE
    S Afr Med J; 1984 Jan; 65(3):86-9. PubMed ID: 6364393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity to halothane metabolite-modified proteins in halothane hepatitis.
    Kenna JG; Knight TL; van Pelt FN
    Ann N Y Acad Sci; 1993 Jun; 685():646-61. PubMed ID: 8363272
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical effects of halothane.
    Acta Anaesthesiol Scand Suppl; 1972; 49():1-43. PubMed ID: 4568644
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.
    Eliasson E; Kenna JG
    Mol Pharmacol; 1996 Sep; 50(3):573-82. PubMed ID: 8794896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sera from patients with halothane hepatitis contain antibodies to halothane-induced liver antigens which are not detectable by immunoblotting.
    Knight TL; Scatchard KM; Van Pelt FN; Kenna JG
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1325-33. PubMed ID: 7932186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoallergic drug-induced hepatitis: lessons from halothane.
    Kenna JG
    J Hepatol; 1997; 26 Suppl 1():5-12. PubMed ID: 9138123
    [No Abstract]   [Full Text] [Related]  

  • 16. Current concept of halothane hepatitis (review).
    Morio M; Fujii K; Yuge O
    In Vivo; 1987; 1(3):163-6. PubMed ID: 2979781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Halothane hepatotoxicity--again?
    Gelman S
    Anesth Analg; 1986 Aug; 65(8):831-4. PubMed ID: 3729017
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane.
    Kenna JG; Satoh H; Christ DD; Pohl LR
    J Pharmacol Exp Ther; 1988 Jun; 245(3):1103-9. PubMed ID: 3385639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Halothane: clinical considerations.
    Morley TS
    Int Anesthesiol Clin; 1974; 12(2):73-84. PubMed ID: 4603053
    [No Abstract]   [Full Text] [Related]  

  • 20. [Halothane hepatitis].
    Dentan M; Desmonts JM; Berthelot P
    Presse Med (1893); 1971 Jun; 79(28):1285-8. PubMed ID: 5563076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.